Congresso

08:00 - 08:20
In patients with resectable distal pancreatic ductal adenocarcinoma, with or without vascular involvement, should Minimally Invasive Distal Pancreatectomy (MIDP) be preferred over Open Distal Pancreatectomy (ODP) whenever feasible to optimize outcomes?

08:00 - 08:20
Discussion and voting

08:20 - 08:40
In patients undergoing minimally invasive surgery for left-sided pancreatic adenocarcinoma, is laparoscopic distal pancreatectomy (LDP) or robotic distal pancreatectomy (RDP) associated with better surgical and oncological outcomes?

08:20 - 08:40
Discussion and voting

08:40 - 09:00
Should Minimally Invasive Enucleation Versus Open Enucleation of Pancreatic Lesions Be Used for Low Grade Neuroendocrine Tumors?

08:40 - 09:00
Discussion and voting

09:00 - 09:20
Should Minimally Invasive Enucleation Versus Open Resection of Pancreatic Lesions Be Used for Neuroendocrine Pancreatic Tumors?

09:00 - 09:20
Discussion and voting

09:40 - 10:00
Debate

10:30 - 10:50
In patients with pancreatic head adenocarcinoma, with or without vascular involvement, should Minimally Invasive Pancreatoduodenectomy (MIPD) be preferred over Open Pancreatoduodenectomy (OPD) to optimize surgical and oncologic outcomes?

10:30 - 10:50
Discussion and voting

10:50 - 11:10
In patients with pancreatic head adenocarcinoma treated with neoadjuvant therapy, should Minimally Invasive Pancreatoduodenectomy (MIPD) be preferred over Open Pancreatoduodenectomy (OPD) to optimize surgical and oncologic outcomes?

10:50 - 11:10
Discussion and voting

11:10 - 11:30
In patients with neuroendocrine tumors (NET) of the pancreatic head, how do minimally invasive approaches (including laparoscopic or robotic pancreatoduodenectomy or enucleation) compared to open techniques in terms of safety, efficacy, and oncologic outc

11:10 - 11:30
Discussion and voting

11:30 - 11:50
In patients requiring total pancreatectomy (for various oncological indications), should Minimally Invasive Total Pancreatectomy (MITP) be preferred over Open Total Pancreatectomy (OTP) to improve perioperative outcomes and long-term results?

11:30 - 11:50
Discussion and voting

11:50 - 12:00
Debate

13:30 - 13:50
In patients with pancreatic cancer undergoing Minimally Invasive Pancreatic Resection, does the addition of multimodal prehabilitation (compared to standard care) improve time to adjuvant therapy, reduce opioid use, enhance quality of life, and lead to be

13:30 - 13:50
Discussion and voting

13:50 - 14:10
What is the role of staging laparoscopy in neoadjuvant therapy and pre-surgical assessment?

13:50 - 14:10
Discussion and voting

14:10 - 14:30
How do Ultrasound, Pancreatoscopy, Frozen section, and Preoperative imaging influence surgical planning in MIPS for Malignant and Pre-Malignant Lesions?

14:10 - 14:30
Discussion and voting

14:30 - 14:50
During Minimally Invasive Pancreatic Surgery, under what circumstances should surgeons opt to convert to an open approach to ensure patient safety, maintain oncologic standards, and optimize perioperative results?

14:30 - 14:50
Discussion and voting

14:50 - 15:30
Debate

16:00 - 16:20
What are the essential prerequisites and training requirements for surgeons initiating Minimally Invasive Pancreatic Resection (MIPR) for cancer, and how should a modern program and surgical team be structured to ensure proficiency, safety, and optimal su

16:00 - 16:20
Discussion and voting

16:20 - 16:40
What is the cost-effectiveness of MIPS versus traditional open pancreatic cancer surgery?

16:20 - 16:40
Discussion and voting

16:40 - 17:00
In patients with pancreatic cancer who are candidates for minimally invasive surgery, how does the cost-effectiveness of robotic pancreatic resection compare to laparoscopic pancreatic resection in terms of direct costs, resource utilization, length of ho

16:40 - 17:00
Discussion and voting

17:00 - 17:20
In patients undergoing Minimally Invasive Pancreatic Resection (MIPR), how do advanced visualization and navigation technologies—along with AI-assisted intraoperative guidance and automation—compared to conventional techniques in terms of surgical precisi

17:00 - 17:20
Discussion and voting

17:20 - 18:00
Debate

08:00 - 08:15
Diagnóstico Precoce Possível: fatores de risco, reconhecimento de sintomas, testes moleculares e IA

08:15 - 08:30
Avanços no diagnóstico por imagem

08:30 - 08:45
Endoscopia: inovações técnicas: spyglass, ecoeda

08:45 - 09:00
Caso Pâncreas Precoce (projeto diagnóstico rápido)

09:00 - 09:15
Rastreamento Populacional é Possível? (grupos de risco, IPMN)

09:15 - 09:30
Prevenção e Políticas de Saúde Pública

09:30 - 09:45
Reconhecimento de Grupos de Risco e Síndromes Hereditárias

09:45 - 10:00
Discussão

10:30 - 10:45
IPMN de Ducto Secundário: Novos limites entre seguimento e cirurgia

10:45 - 11:00
Adenoma-Cístico Mucinoso: novos paradigmas?

11:00 - 11:15
Tumor de Frantz - Workup e resultados

11:15 - 11:30
Caso de IPMN ou Cistos com indicação cirúrgica

11:30 - 11:45
Manejo de Cistos Pancreáticos além dos Guidelines Atuais

11:45 - 12:00
Discussão e Caso

13:30 - 13:45
Work up Diagnóstico

13:45 - 14:00
Síndromes Funcionais

14:00 - 14:15
Tratamento Cirúrgico (Cirurgia Conservadora e de Preservação Tecidual, Seguimento ativo)

14:15 - 14:30
Terapia Sistêmica

14:30 - 14:45
Avanços na Pesquisa Clínica

14:45 - 15:00
Caso Clínico - Tumor Board

15:00 - 15:30
Discussão TNE pancreático

16:00 - 16:15
Cudiados clínicos e peri-operatórios em pancreatectomia total

16:15 - 16:30
Insuficiência Exócrina

16:30 - 16:45
Pré-Habilitação Personalizada e prevenção de complicações

16:45 - 17:00
Suporte Nutricional em pancreatectomias

17:00 - 17:15
Gestão Multidisciplinar com Suporte Paliativo, Psiquíco e Espiritual

17:15 - 17:30
Discussão

17:30 - 17:50
Distinguished Keynote Lecture: ADVOCACY IN PANCREATIC CANCER

17:50 - 18:00
Discussão

08:00 - 08:15
Biomarcadores Líquidos e Células Tumorais Circulantes

08:15 - 08:30
Inteligência Artificial e Big Data no Câncer de Pâncreas (diagnóstico precoce, Modelos Digitais e Simulação Clínica, Digital Twin)

08:30 - 08:45
Perspectivas de Pesquisa em Adenocarcinoma

08:45 - 09:00
Influência do Microbioma e Interações Host-Tumor

09:00 - 09:15
O futuro das Terapias locais (Eletroporação, Radioterapia Estereotáxica, Ablação endoscópica)

09:15 - 09:30
Novas Tecnologias e Plataformas em Cirurgia Robóticas

09:30 - 10:00
Discussão e Caso

10:30 - 10:45
Neoadjuvância para quem e porque? Qual melhor esquema?

10:45 - 11:00
Qual o papel atual da Radioterapia?

11:00 - 11:15
Terapia Multidisciplinar na Doença oligometastática?

11:15 - 11:30
O que fazer em 2a e 3a Linhas?

11:30 - 11:45
Novas Drogas e Perspectivas Futuras

11:45 - 12:00
Terpia Alvo em Câncer de Pâncreas

12:00 - 12:15
Discussão

13:30 - 13:45
Ressecção Venosa Complexa

13:45 - 14:00
Ressecção e Reconstrução Arterial Complexa (reconstrução microcirúrgica)

14:00 - 14:15
Papel das cirurgias de Resgate em recidivas locorregionais?

14:15 - 14:30
Pancreatectomias laparoscópicas: Tips and Tricks

14:30 - 14:45
Whipple Robótica. Lessons Learned in the last decade!

14:45 - 15:00
Tratamento de Complicações Vasculares e Biliares

15:00 - 15:30
Discussão e Caso - Caso de sangramento pós operatório / Sequência do cuidado

16:00 - 16:15
Cart T, NK, Macrófago no Câncer de Pâncreas

16:15 - 16:30
Inovação em terapia Sistêmica no Câncer de Pâncreas

16:30 - 16:45
Ressecções pancreáticas por tumores não pancreáticos

16:45 - 17:00
Microambiente Tumoral e Terapias de Modulação do Estroma

17:00 - 17:15
A jornada de um paciente!

17:15 - 17:30
Qualidade de Vida em Câncer de Pâncreas

17:30 - 17:55
Discussão e Caso

17:55 - 18:00
Considerações Finais e Encerramento